TY - JOUR
T1 - Identifying consensus and areas for future research in chondrosarcoma
T2 - a report from the Birmingham Orthopaedic Oncology Meeting
AU - Jeys, Lee M
AU - Morris, Guy V
AU - Kurisunkal, Vineet J
AU - Botello, Eduardo
AU - Boyle, Richard A
AU - Ebeid, Walid
AU - Houdek, Matthew T
AU - Puri, Ajay
AU - Ruggieri, Pietro
AU - Brennan, Bernadette
AU - Laitinen, Minna K
AU - Abad Repiso, Santiago
AU - Abdelbary, Hesham
AU - Abiad Mejia, Alejandro
AU - Abood, Ahmed A
AU - Abril Martin, Juan C
AU - Abudu, Adesegun
AU - Abu Elhamd, Ayman
AU - Acosta, Marthelena
AU - Ae, Keisuke
AU - Agarwal, Manish
AU - Ajit Singh, Vivek
AU - Akiyama, Toru
AU - Alshaygy, Ibrahim
AU - Albergo, Jose I
AU - Alexander, John
AU - Alfaro, Patricio A
AU - Alpan, Bugra
AU - Amaya-Valero, Jose
AU - Anderson, Megan
AU - Andreou, Dimosthenis
AU - Annabell, Lucas
AU - Anthony, Christopher
AU - Aoude, Ahmed
AU - Arteagoitia-Colino, Iraia
AU - Asavamongkolkul, Apichat
AU - Aston, William
AU - Asua Mentxaka, Libe
AU - Azzopardi, Christine
AU - Baad-Hansen, Thomas
AU - Badr, Ismail T
AU - Baixauli-Garcia, Francisco
AU - Baker, Gavin
AU - Balach, Tessa
AU - Baldi, Giacomo G
AU - Barry, Janie
AU - Basile, Georges
AU - Bastoni, Stefano
AU - BOOM Consensus Meeting participants
A2 - Basuki, Mohammad
A2 - Petersen, Michael M
N1 - © 2025 Jeys et al.
PY - 2025/2/1
Y1 - 2025/2/1
N2 - AIMS: The Birmingham Orthopaedic Oncology Meeting (BOOM), held in January 2024, convened 309 delegates from 53 countries to discuss and refine 21 consensus statements on the optimal management of chondrosarcoma.METHODS: With representation from Europe (43%; n = 133), North America (17%; n = 53), South America (16%; n = 49), Asia (13%; n = 40), Australasia (5%; n = 16), the Middle East (4%; n = 12), and Africa (2%; n = 6), the combined experience of treating bone sarcomas among attendees totalled approximately 30,000 cases annually, equivalent to 66 years of experience in the UK alone. The meeting's process began with the formation of a local organizing committee, regional leads, and a scientific committee comprising representatives from 150 specialist units across 47 countries. Supported by major orthopaedic oncology organizations, the meeting used a modified Delphi process to develop consensus statements through online questionnaires, thematic groupings, narrative reviews, and anonymous pre-meeting polling.RESULTS: Strong (> 80%) consensus was achieved on 19 out of 21 statements, reflecting agreement among delegates. Key areas of consensus included the role of radiology in diagnosis and surveillance, the management of locally recurrent disease, and the treatment of dedifferentiated chondrosarcoma. Notably, there was agreement that routine chemotherapy has no role in chondrosarcoma treatment, and radiological surveillance is safe for intraosseous chondrosarcomas. Despite the overall consensus, areas of controversy remain, particularly regarding the treatment of atypical cartilage tumours and surgical margins. These unresolved issues underscore the need for further research and collaboration within the orthopaedic oncology community.CONCLUSION: BOOM represents the largest global consensus meeting in orthopaedic oncology, providing valuable guidance for clinicians managing chondrosarcoma worldwide. The consensus statements offer a reference for clinical practice, highlight key research priorities, and aim to improve patient outcomes on a global scale.
AB - AIMS: The Birmingham Orthopaedic Oncology Meeting (BOOM), held in January 2024, convened 309 delegates from 53 countries to discuss and refine 21 consensus statements on the optimal management of chondrosarcoma.METHODS: With representation from Europe (43%; n = 133), North America (17%; n = 53), South America (16%; n = 49), Asia (13%; n = 40), Australasia (5%; n = 16), the Middle East (4%; n = 12), and Africa (2%; n = 6), the combined experience of treating bone sarcomas among attendees totalled approximately 30,000 cases annually, equivalent to 66 years of experience in the UK alone. The meeting's process began with the formation of a local organizing committee, regional leads, and a scientific committee comprising representatives from 150 specialist units across 47 countries. Supported by major orthopaedic oncology organizations, the meeting used a modified Delphi process to develop consensus statements through online questionnaires, thematic groupings, narrative reviews, and anonymous pre-meeting polling.RESULTS: Strong (> 80%) consensus was achieved on 19 out of 21 statements, reflecting agreement among delegates. Key areas of consensus included the role of radiology in diagnosis and surveillance, the management of locally recurrent disease, and the treatment of dedifferentiated chondrosarcoma. Notably, there was agreement that routine chemotherapy has no role in chondrosarcoma treatment, and radiological surveillance is safe for intraosseous chondrosarcomas. Despite the overall consensus, areas of controversy remain, particularly regarding the treatment of atypical cartilage tumours and surgical margins. These unresolved issues underscore the need for further research and collaboration within the orthopaedic oncology community.CONCLUSION: BOOM represents the largest global consensus meeting in orthopaedic oncology, providing valuable guidance for clinicians managing chondrosarcoma worldwide. The consensus statements offer a reference for clinical practice, highlight key research priorities, and aim to improve patient outcomes on a global scale.
KW - Chondrosarcoma/therapy
KW - Humans
KW - Bone Neoplasms/therapy
KW - Consensus
KW - Orthopedics
KW - Delphi Technique
UR - https://www.scopus.com/pages/publications/85217732060
U2 - 10.1302/0301-620X.107B2.BJJ-2024-0643.R1
DO - 10.1302/0301-620X.107B2.BJJ-2024-0643.R1
M3 - Journal article
C2 - 39889743
SN - 2049-4394
VL - 107-B
SP - 246
EP - 252
JO - The bone & joint journal
JF - The bone & joint journal
IS - 2
ER -